Literature DB >> 24313885

Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease.

Sedat Yilmaz1, Muhammet Cinar, Ismail Simsek, Hakan Erdem, Salih Pay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24313885     DOI： 10.3109/14397595.2013.854437

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN： 1439-7595            Impact factor:   3.023


× No keyword cloud information.
  3 in total

1.  Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature.

Authors:  Catharina M Mulders-Manders; Marije C Baas; Femke M Molenaar; Anna Simon
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

2.  Biological treatment in resistant adult-onset Still's disease: A single-center, retrospective cohort study.

Authors:  Seda Çolak; Emre Tekgöz; Maghrur Mammadov; Muhammet Çınar; Sedat Yılmaz
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.007

3.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.